Prevalence of immune-related adverse events (irAEs) and association with symptom distress score by Edmonton Symptom Assessment System (ESAS) in solid cancer patients receiving immune checkpoint inhibitor (ICI) therapy.

Authors: Sudpreeda Chainitikun, Siyamol Mingmalairak, Panida Saetan, Siriwan Tangjitgamol

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e23191

Source: Full article

e23191